{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:36:00Z","timestamp":1792398960553,"version":"4.4.0"},"reference-count":102,"publisher":"SAGE Publications","issue":"s2","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JND"],"published-print":{"date-parts":[[2021,11,30]]},"abstract":"<jats:p>Duchenne muscular dystrophy (DMD) is an X-linked, muscle wasting disease that affects 1 in 5000 males. Affected individuals become wheelchair bound by the age of twelve and eventually die in their third decade due to respiratory and cardiac complications. The disease is caused by mutations in the DMD gene that codes for dystrophin. Dystrophin is a structural protein that maintains the integrity of muscle fibres and protects them from contraction-induced damage. The absence of dystrophin compromises the stability and function of the muscle fibres, eventually leading to muscle degeneration. So far, there is no effective treatment for deteriorating muscle function in DMD patients. A promising approach for treating this life-threatening disease is gene transfer to restore dystrophin expression using a safe, non-pathogenic viral vector called adeno-associated viral (AAV) vector. Whilst microdystrophin gene transfer using AAV vectors shows extremely impressive therapeutic success so far in large animal models of DMD, translating this advanced therapy medicinal product from bench to bedside still offers scope for many optimization steps. In this paper, the authors review the current progress of AAV-microdystrophin gene therapy for DMD and other treatment strategies that may apply to a subset of DMD patients depending on the mutations they carry.<\/jats:p>","DOI":"10.3233\/jnd-210678","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T13:19:39Z","timestamp":1631279979000},"page":"S303-S316","source":"Crossref","is-referenced-by-count":182,"title":["Gene Therapy for Duchenne Muscular Dystrophy"],"prefix":"10.1177","volume":"8","author":[{"given":"Nertiyan","family":"Elangkovan","sequence":"first","affiliation":[{"name":"Centres for Gene & Cell Therapy and Biomedical Sciences, Department of Biological Sciences, School of Life & Environmental Sciences, Royal Holloway - University of London, Surrey, TW20 0EX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Dickson","sequence":"additional","affiliation":[{"name":"Centres for Gene & Cell Therapy and Biomedical Sciences, Department of Biological Sciences, School of Life & Environmental Sciences, Royal Holloway - University of London, Surrey, TW20 0EX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JND-210678_ref1","doi-asserted-by":"crossref","unstructured":"Angelini C . Muscular dystrophy. Handbook of clinical neurology: Elsevier; 2009. p. 477\u2013488.","DOI":"10.1016\/S0072-9752(08)02131-3"},{"issue":"1","key":"10.3233\/JND-210678_ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nature Reviews Disease Primers"},{"issue":"9307","key":"10.3233\/JND-210678_ref3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(02)07815-7","article-title":"The muscular dystrophies","volume":"359","author":"Emery","year":"2002","journal-title":"The Lancet"},{"issue":"3","key":"10.3233\/JND-210678_ref5","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0092-8674(87)90504-6","article-title":"Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals","volume":"50","author":"Koenig","year":"1987","journal-title":"Cell"},{"issue":"2","key":"10.3233\/JND-210678_ref6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0092-8674(88)90383-2","article-title":"The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein","volume":"53","author":"Koenig","year":"1988","journal-title":"Cell"},{"issue":"21","key":"10.3233\/JND-210678_ref7","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1016\/j.jacc.2016.02.081","article-title":"Dystrophin-deficient cardiomyopathy","volume":"67","author":"Kamdar","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"10213","key":"10.3233\/JND-210678_ref8","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/S0140-6736(19)32910-1","article-title":"Muscular dystrophies","volume":"394","author":"Mercuri","year":"2019","journal-title":"The Lancet. 3943)"},{"issue":"1","key":"10.3233\/JND-210678_ref9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms16105","article-title":"Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy","volume":"8","author":"Le Guiner","year":"2017","journal-title":"Nature Communications"},{"key":"10.3233\/JND-210678_ref10","doi-asserted-by":"crossref","unstructured":"Abdul-Razak H , Malerba A , Dickson G . Advances in gene therapy for muscular dystrophies. F1000Research. 2016;5.","DOI":"10.12688\/f1000research.8735.1"},{"issue":"10","key":"10.3233\/JND-210678_ref11","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/nrg1180","article-title":"Advances in Duchenne muscular dystrophy gene therapy","volume":"4","author":"Van Deutekom","year":"2003","journal-title":"Nature Reviews Genetics"},{"issue":"10","key":"10.3233\/JND-210678_ref12","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nrm2024","article-title":"Molecular mechanisms of muscular dystrophies: old and new players","volume":"7","author":"Davies","year":"2006","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"6","key":"10.3233\/JND-210678_ref13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrg3460","article-title":"Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches","volume":"14","author":"Fairclough","year":"2013","journal-title":"Nature Reviews Genetics"},{"issue":"2","key":"10.3233\/JND-210678_ref14","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/mus.26518","article-title":"Dystrophin is expressed in smooth muscle and afferent nerve fibers in the rat urinary bladder","volume":"60","author":"Lionarons","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.3233\/JND-210678_ref15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.mcn.2013.04.005","article-title":"Splicing therapy for neuromuscular disease","volume":"56","author":"Douglas","year":"2013","journal-title":"Molecular and Cellular Neuroscience"},{"issue":"1","key":"10.3233\/JND-210678_ref16","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1152\/physrev.00007.2015","article-title":"Absence of dystrophin disrupts skeletal muscle signaling: roles of Ca2, reactive oxygen species, and nitric oxide in the development of muscular dystrophy","volume":"96","author":"Allen","year":"2016","journal-title":"Physiol Rev"},{"issue":"3","key":"10.3233\/JND-210678_ref17","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1172\/JCI36612","article-title":"Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy","volume":"119","author":"Lai","year":"2009","journal-title":"J Clin Invest"},{"issue":"2","key":"10.3233\/JND-210678_ref18","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1073\/pnas.1211431109","article-title":"\u03b12 and \u03b13 helices of dystrophin R16 and R17 frame a microdomain in the \u03b11 helix of dystrophin R17 for neuronal NOS binding","volume":"110","author":"Lai","year":"2013","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"7","key":"10.3233\/JND-210678_ref19","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1089\/hum.2018.012","article-title":"Micro-dystrophin gene therapy goes systemic in Duchenne muscular dystrophy patients","volume":"29","author":"Duan","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"6273","key":"10.3233\/JND-210678_ref20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/345315a0","article-title":"Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle","volume":"345","author":"Ervasti","year":"1990","journal-title":"Nature"},{"issue":"6273","key":"10.3233\/JND-210678_ref21","first-page":"315","article-title":"Glycoprotein complex anchoring dystrophin to sarcolemma","volume":"345","author":"Yoshida","year":"1990","journal-title":"The Journal of Biochemistry"},{"issue":"12","key":"10.3233\/JND-210678_ref22","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/mus.1192","article-title":"The dystrophin\u2013glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies","volume":"24","author":"Rando","year":"2001","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.3233\/JND-210678_ref23","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1089\/hum.2012.099","article-title":"Genetic therapeutic approaches for Duchenne muscular dystrophy","volume":"23","author":"Foster","year":"2012","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.3233\/JND-210678_ref24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2044-5040-3-9","article-title":"Vascular-targeted therapies for Duchenne muscular dystrophy","volume":"3","author":"Ennen","year":"2013","journal-title":"Skeletal Muscle"},{"issue":"6254","key":"10.3233\/JND-210678_ref25","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/343180a0","article-title":"Very mild muscular dystrophy associated with the deletion of 46% of dystrophin","volume":"343","author":"England","year":"1990","journal-title":"Nature"},{"issue":"4","key":"10.3233\/JND-210678_ref26","first-page":"498","article-title":"The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion","volume":"45","author":"Koenig","year":"1989","journal-title":"Am J Hum Genet"},{"issue":"3685","key":"10.3233\/JND-210678_ref27","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1126\/science.149.3685.754","article-title":"Adenovirus-associated defective virus particles","volume":"149","author":"Atchison","year":"1965","journal-title":"Science"},{"issue":"4","key":"10.3233\/JND-210678_ref28","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1073\/pnas.58.4.1410","article-title":"Isolation of adenovirus-associated viruses from man","volume":"58","author":"Blacklow","year":"1967","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.3233\/JND-210678_ref29","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nature Reviews Drug Discovery"},{"issue":"20","key":"10.3233\/JND-210678_ref30","doi-asserted-by":"crossref","first-page":"6466","DOI":"10.1073\/pnas.81.20.6466","article-title":"Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells","volume":"81","author":"Hermonat","year":"1984","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"9","key":"10.3233\/JND-210678_ref31","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1089\/hum.1996.7.9-1145","article-title":"A phase i study of an adeno-associated virus-cftr gene vector in adult cf patients with mild lung disease. Johns hopkins children\u2019s center, baltimore, maryland","volume":"7","author":"Flotte","year":"1996","journal-title":"Hum Gene Ther"},{"issue":"10","key":"10.3233\/JND-210678_ref32","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/mt.2012.194","article-title":"Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union","volume":"20","author":"Yl\u00e4-Herttuala","year":"2012","journal-title":"Molecular Therapy"},{"issue":"6","key":"10.3233\/JND-210678_ref33","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/13816810.2018.1533027","article-title":"Gene therapy for RPE65-related retinal disease","volume":"39","author":"Miraldi Utz","year":"2018","journal-title":"Ophthalmic Genet"},{"issue":"11","key":"10.3233\/JND-210678_ref34","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","article-title":"Onasemnogene abeparvovec: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"issue":"9","key":"10.3233\/JND-210678_ref35","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1128\/jvi.63.9.3822-3828.1989","article-title":"Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression","volume":"63","author":"Samulski","year":"1989","journal-title":"J Virol"},{"issue":"7","key":"10.3233\/JND-210678_ref36","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrg3742","article-title":"Engineering adeno-associated viruses for clinical gene therapy","volume":"15","author":"Kotterman","year":"2014","journal-title":"Nature Reviews Genetics"},{"issue":"10","key":"10.3233\/JND-210678_ref37","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.gt.3302233","article-title":"Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors","volume":"11","author":"Flotte","year":"2004","journal-title":"Gene Ther"},{"issue":"11","key":"10.3233\/JND-210678_ref38","doi-asserted-by":"crossref","first-page":"8568","DOI":"10.1128\/JVI.72.11.8568-8577.1998","article-title":"Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue","volume":"72","author":"Duan","year":"1998","journal-title":"J Virol"},{"issue":"2","key":"10.3233\/JND-210678_ref39","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/mt.2015.187","article-title":"Production of recombinant adeno-associated virus vectors using suspension HEK293 cells and continuous harvest of vector from the culture media for GMP FIX and FLT1 clinical vector","volume":"24","author":"Grieger","year":"2016","journal-title":"Molecular Therapy"},{"key":"10.3233\/JND-210678_ref40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Molecular Therapy-Methods & Clinical Development"},{"issue":"12","key":"10.3233\/JND-210678_ref41","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1128\/JVI.78.12.6381-6388.2004","article-title":"Clades of Adeno-associated viruses are widely disseminated in human tissues","volume":"78","author":"Gao","year":"2004","journal-title":"J Virol"},{"key":"10.3233\/JND-210678_ref42","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ymthe.2006.05.009","article-title":"Adeno-associated virus serotypes: vector toolkit for human gene therapy","volume":"14","author":"Wu","year":"2006","journal-title":"Mol Ther"},{"issue":"11","key":"10.3233\/JND-210678_ref43","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1172\/JCI8317","article-title":"Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus","volume":"105","author":"Duan","year":"2000","journal-title":"J Clin Invest"},{"key":"10.3233\/JND-210678_ref44","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1146\/annurev-virology-092818-015530","article-title":"Recombinant adeno-associated virus gene therapy in light of Luxturna (and Zolgensma and Glybera): where are we, and how did we get here?","volume":"6","author":"Keeler","year":"2019","journal-title":"Annual Review of Virology"},{"issue":"1","key":"10.3233\/JND-210678_ref45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/mt.2009.256","article-title":"Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome\u22658.2kb","volume":"18","author":"Lai","year":"2010","journal-title":"Molecular Therapy"},{"issue":"1","key":"10.3233\/JND-210678_ref46","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/mt.2009.255","article-title":"Effect of genome size on AAV vector packaging","volume":"18","author":"Wu","year":"2010","journal-title":"Molecular Therapy"},{"issue":"1","key":"10.3233\/JND-210678_ref47","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/mt.2009.258","article-title":"Characterization of genome integrity for oversized recombinant AAV vector","volume":"18","author":"Dong","year":"2010","journal-title":"Molecular Therapy"},{"issue":"25","key":"10.3233\/JND-210678_ref48","doi-asserted-by":"crossref","first-page":"13714","DOI":"10.1073\/pnas.240335297","article-title":"Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model","volume":"97","author":"Wang","year":"2000","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"3","key":"10.3233\/JND-210678_ref49","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nm0302-253","article-title":"Modular flexibility of dystroph: implications for gene therapy of Duchenne muscular dystrophy","volume":"8","author":"Harper","year":"2002","journal-title":"Nat Med"},{"key":"10.3233\/JND-210678_ref50","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.omtm.2017.06.006","article-title":"A five-repeat micro-dystrophin gene ameliorated dystrophic phenotype in the severe DBA\/2J-mdx model of Duchenne muscular dystrophy","volume":"6","author":"Hakim","year":"2017","journal-title":"Molecular Therapy-Methods & Clinical Development"},{"issue":"18","key":"10.3233\/JND-210678_ref51","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.3233\/JND-210678_ref55","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41582-019-0203-3","article-title":"Therapeutic developments for Duchenne muscular dystrophy","volume":"15","author":"Verhaart","year":"2019","journal-title":"Nature Reviews Neurology"},{"issue":"1","key":"10.3233\/JND-210678_ref56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2016.0657","article-title":"FDA approves eteplirsen for Duchenne muscular dystrophy: the next chapter in the eteplirsen saga","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Therapeutics"},{"key":"10.3233\/JND-210678_ref57","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.omtn.2017.09.002","article-title":"Rational design of short locked nucleic acid-modified 2\u2032-O-methyl antisense oligonucleotides for efficient exon-skipping in vitro","volume":"9","author":"Le","year":"2017","journal-title":"Molecular Therapy-Nucleic Acids"},{"issue":"2","key":"10.3233\/JND-210678_ref58","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00431-018-3272-1","article-title":"Injection site reactions after long-term subcutaneous delivery of drisapersen: a retrospective study","volume":"178","author":"Hilhorst","year":"2019","journal-title":"Eur J Pediatr"},{"issue":"1","key":"10.3233\/JND-210678_ref59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-22316-7","article-title":"Assisted delivery of antisense therapeutics in animal models of heritable neurodegenerative and neuromuscular disorders: a systematic review and meta-analysis","volume":"8","author":"van der Bent","year":"2018","journal-title":"Scientific Reports"},{"key":"10.3233\/JND-210678_ref60","doi-asserted-by":"crossref","first-page":"S166","DOI":"10.1016\/j.nmd.2020.09.008","article-title":"LATE BREAKING NEWS ORAL PRESENTATION: LBO 3 Expression of apparent full-length dystrophin in skeletal muscle in a first-in-human gene therapy trial using the scAAV9","volume":"30","author":"Waldrop","year":"2020","journal-title":"U7-ACCA vector. Neuromuscular Disorders"},{"issue":"5","key":"10.3233\/JND-210678_ref62","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.ymthe.2017.02.019","article-title":"Progress toward gene therapy for Duchenne muscular dystrophy","volume":"25","author":"Chamberlain","year":"2017","journal-title":"Molecular Therapy"},{"issue":"7","key":"10.3233\/JND-210678_ref63","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1089\/hum.2013.081","article-title":"Gene correction of a duchenne muscular dystrophy mutation by meganuclease-enhanced exon knock-in","volume":"24","author":"Popplewell","year":"2013","journal-title":"Hum Gene Ther"},{"issue":"3","key":"10.3233\/JND-210678_ref64","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/mt.2016.5","article-title":"Current progress in therapeutic gene editing for monogenic diseases","volume":"24","author":"Prakash","year":"2016","journal-title":"Molecular Therapy"},{"issue":"4","key":"10.3233\/JND-210678_ref65","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/jpm8040038","article-title":"Applications of CRISPR\/Cas9 for the treatment of Duchenne muscular dystrophy","volume":"8","author":"Lim","year":"2018","journal-title":"Journal of Personalized Medicine"},{"issue":"9","key":"10.3233\/JND-210678_ref66","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.ymthe.2019.06.012","article-title":"AAV9 edits muscle stem cells in normal and dystrophic adult mice","volume":"27","author":"Nance","year":"2019","journal-title":"Molecular Therapy"},{"key":"10.3233\/JND-210678_ref67","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.omtm.2020.09.016","article-title":"In vivo gene editing of muscle stem cells with adeno-associated viral vectors in a mouse model of Duchenne muscular dystrophy","volume":"19","author":"Kwon","year":"2020","journal-title":"Molecular Therapy-Methods & Clinical Development"},{"issue":"1","key":"10.3233\/JND-210678_ref68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-05843-9","article-title":"Cas9 immunity creates challenges for CRISPR gene editing therapies","volume":"9","author":"Crudele","year":"2018","journal-title":"Nature Communications"},{"issue":"3","key":"10.3233\/JND-210678_ref69","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J Infect Dis"},{"issue":"1","key":"10.3233\/JND-210678_ref70","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1538-7836.2006.02262.x","article-title":"It\u2019s all about the clothing: capsid domination in the adeno-associated viral vector world","volume":"5","author":"Arruda","year":"2007","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.3233\/JND-210678_ref71","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fmicb.2011.00201","article-title":"Immunity and AAV-mediated gene therapy for muscular dystrophies in large animal models and human trials","volume":"2","author":"Wang","year":"2011","journal-title":"Frontiers in Microbiology"},{"issue":"8","key":"10.3233\/JND-210678_ref72","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/mt.2010.94","article-title":"Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs","volume":"18","author":"Kornegay","year":"2010","journal-title":"Molecular Therapy"},{"issue":"3","key":"10.3233\/JND-210678_ref73","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.3233\/JND-210678_ref74","first-page":"23","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"4","key":"10.3233\/JND-210678_ref75","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2174\/1566523215666150630121750","article-title":"The skeletal muscle environment and its role in immunity and tolerance to AAV vector-mediated gene transfer","volume":"15","author":"Boisgerault","year":"2015","journal-title":"Current Gene Therapy"},{"issue":"12","key":"10.3233\/JND-210678_ref76","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1172\/JCI70314","article-title":"Human Treg responses allow sustained recombinant adeno-associated virus\u2013mediated transgene expression","volume":"123","author":"Mueller","year":"2013","journal-title":"J Clin Invest"},{"issue":"13","key":"10.3233\/JND-210678_ref77","first-page":"3038","article-title":"Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer","volume":"119","author":"Buchlis","year":"2012","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"10.3233\/JND-210678_ref78","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3389\/fmicb.2011.00194","article-title":"Innate immune responses to AAV vectors","volume":"2","author":"Rogers","year":"2011","journal-title":"Frontiers in Microbiology"},{"issue":"21","key":"10.3233\/JND-210678_ref79","doi-asserted-by":"crossref","first-page":"15319","DOI":"10.1074\/jbc.R700009200","article-title":"Toll-like receptors and Type I interferons","volume":"282","author":"Uematsu","year":"2007","journal-title":"J Biol Chem"},{"issue":"3","key":"10.3233\/JND-210678_ref80","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ymthe.2020.01.026","article-title":"Codon Modification and PAMPs in Clinical AAV Vectors: The Tortoise or the Hare?","volume":"28","author":"Wright","year":"2020","journal-title":"Molecular Therapy"},{"issue":"24","key":"10.3233\/JND-210678_ref81","first-page":"6459","article-title":"The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9\u2013dependent innate immune responses in the liver","volume":"117","author":"Martino","year":"2011","journal-title":"Blood. The Journal of the American Society of Hematology"},{"issue":"7","key":"10.3233\/JND-210678_ref82","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1172\/JCI68205","article-title":"CpG-depleted adeno-associated virus vectors evade immune detection","volume":"123","author":"Faust","year":"2013","journal-title":"J Clin Invest"},{"key":"10.3233\/JND-210678_ref83","doi-asserted-by":"crossref","unstructured":"Matthews E , Brassington R , Kuntzer T , Jichi F , Manzur AY . Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database of Systematic Reviews. 2016(5).","DOI":"10.1002\/14651858.CD003725.pub4"},{"issue":"299","key":"10.3233\/JND-210678_ref84","doi-asserted-by":"crossref","first-page":"299rv4","DOI":"10.1126\/scitranslmed.aaa7322","article-title":"Immune-mediated pathology in Duchenne muscular dystrophy","volume":"7","author":"Rosenberg","year":"2015","journal-title":"Science Translational Medicine"},{"issue":"4","key":"10.3233\/JND-210678_ref85","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ymthe.2017.02.004","article-title":"Systemic AAV8-mediated gene therapy drives whole-body correction of myotubular myopathy in dogs","volume":"25","author":"Mack","year":"2017","journal-title":"Molecular Therapy"},{"issue":"3","key":"10.3233\/JND-210678_ref87","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ymthe.2018.01.018","article-title":"The neurotropic properties of AAV-PHP. B are limited to C57BL\/6J mice","volume":"26","author":"Hordeaux","year":"2018","journal-title":"Molecular Therapy"},{"issue":"20","key":"10.3233\/JND-210678_ref88","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.1093\/hmg\/ddv310","article-title":"Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus","volume":"24","author":"Yue","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.3233\/JND-210678_ref89","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coviro.2016.07.006","article-title":"Systemic delivery of adeno-associated viral vectors","volume":"21","author":"Duan","year":"2016","journal-title":"Current Opinion in Virology"},{"issue":"2","key":"10.3233\/JND-210678_ref90","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI79213","article-title":"Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy","volume":"125","author":"Chandler","year":"2015","journal-title":"J Clin Invest"},{"issue":"10","key":"10.3233\/JND-210678_ref91","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ng.3407","article-title":"Adeno-associated virus finds its disease","volume":"47","author":"Russell","year":"2015","journal-title":"Nat Genet"},{"issue":"21","key":"10.3233\/JND-210678_ref92","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.3233\/JND-210678_ref93","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/mt.2016.52","article-title":"Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients","volume":"24","author":"Gil-Farina","year":"2016","journal-title":"Molecular Therapy"},{"key":"10.3233\/JND-210678_ref95","unstructured":"Gene Therapy Trials: Pfizer. PPMD 2019 Annual Conference; 28 June 2019; Orlando Florida."},{"issue":"102","key":"10.3233\/JND-210678_ref96","first-page":"49","article-title":"Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy","volume":"19","author":"Powell","year":"2015","journal-title":"Discovery Medicine"},{"issue":"6","key":"10.3233\/JND-210678_ref97","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.celrep.2015.07.019","article-title":"In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector","volume":"12","author":"Zinn","year":"2015","journal-title":"Cell Reports"},{"issue":"12","key":"10.3233\/JND-210678_ref98","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1089\/hum.2015.107","article-title":"Perspective on adeno-associated virus capsid modification for Duchenne muscular dystrophy gene therapy","volume":"26","author":"Nance","year":"2015","journal-title":"Hum Gene Ther"},{"key":"10.3233\/JND-210678_ref99","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2147\/TCRM.S172291","article-title":"Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives","volume":"15","author":"Dangouloff","year":"2019","journal-title":"Therapeutics and Clinical Risk Management"},{"issue":"7","key":"10.3233\/JND-210678_ref100","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1177\/0192623317734823","article-title":"Duchenne and Becker muscular dystrophies: a review of animal models, clinical end points, and biomarker quantification","volume":"45","author":"Wilson","year":"2017","journal-title":"Toxicol Pathol"},{"key":"10.3233\/JND-210678_ref101","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.phrs.2018.09.007","article-title":"Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug","volume":"136","author":"Conklin","year":"2018","journal-title":"Pharmacological Research"},{"issue":"1","key":"10.3233\/JND-210678_ref102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-06621-3","article-title":"Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration","volume":"9","author":"Meliani","year":"2018","journal-title":"Nature Communications"},{"issue":"10","key":"10.3233\/JND-210678_ref103","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Molecular Therapy"},{"key":"10.3233\/JND-210678_ref105","unstructured":"Gene Therapy Trials: Solid Biosciences.. PPMD 2019 Annual Conference; 28 June 2019; Orlando Florida."},{"key":"10.3233\/JND-210678_ref110","unstructured":"Gene Therapy Trials: Sarepta.. PPMD 2019 Annual Conference; 28 June 2019; Orlando Florida."},{"key":"10.3233\/JND-210678_ref111","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1016\/j.nmd.2020.08.277","article-title":"DMD\u2013THERAPY: P. 280 Systemic gene transfer with rAAVrh74. MHCK7. micro-dystrophin in patients with Duchenne muscular dystrophy","volume":"30","author":"Mendell","year":"2020","journal-title":"Neuromuscular Disorders"},{"key":"10.3233\/JND-210678_ref112","doi-asserted-by":"crossref","unstructured":"Mullard A . Sarepta\u2019s DMD gene therapy falls flat. Nature Reviews Drug Discovery. 2021;20(91).","DOI":"10.1038\/d41573-021-00010-0"},{"issue":"6","key":"10.3233\/JND-210678_ref114","doi-asserted-by":"crossref","first-page":"e21628","DOI":"10.1096\/fj.202100057RR","article-title":"Long-term effect of human mini-dystrophin in transgenic mdx mice improves muscle physiological function","volume":"35","author":"Chu","year":"2021","journal-title":"The FASEB Journal"},{"issue":"17","key":"10.3233\/JND-210678_ref115","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1093\/hmg\/ddy197","article-title":"Syntrophin binds directly to multiple spectrin-like repeats in dystrophin and mediates binding of nNOS to repeats 16\u201317","volume":"27","author":"Adams","year":"2018","journal-title":"Hum Mol Genet"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JND-210678","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:49:49Z","timestamp":1777506589000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JND-210678"}},"subtitle":[],"editor":[{"given":"Jyoti","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Kanneboyina","family":"Nagaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":102,"journal-issue":{"issue":"s2"},"URL":"https:\/\/doi.org\/10.3233\/jnd-210678","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,30]]}}}